Andrew Zolot, MD
Ophthalmology · Greenfield, WINPI 1285258574
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,903 of the $6,246 with a category attached, or 62.5%. 18 manufacturers reported payments, led by Glaukos Corporation at 38.1% of the total. 2025 is the largest year on record at $2,564, 5.3 times the $485 reported in 2021. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $102.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$2K
- Sight Sciences, Inc.$385
- Bausch & Lomb Americas Inc.$282
- NEW World Medical,inc.$274
- AbbVie$223
- plus $881 from 12 others
What the payments were for
- Travel & lodging$2,34338%
- Food & beverage$3,90362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 11 | $2,379 |
| Alcon | 16 | $1,822 |
| Sight Sciences, Inc. | 4 | $385 |
| Bausch & Lomb Americas Inc. | 4 | $282 |
| NEW World Medical,inc. | 7 | $274 |
| AbbVie | 4 | $223 |
| Amgen | 2 | $145 |
| Apellis Pharmaceuticals, Inc. | 2 | $132 |
| Regeneron | 1 | $132 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $109 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Eyepoint US, Inc. | 1 | $81 |
| Alimera Sciences, Inc. | 1 | $41 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $39 |
| Johnson & Johnson | 1 | $32 |
| Spark Therapeutics, Inc. | 1 | $31 |
| Dompe US, Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Radius XR$2,049
- Travoprost Intraocular Implant - iDose$2,049
- iStent Infinite$2,049
- Clareon$421
- OMNI(R) SURGICAL SYSTEM (US)$323
- Tecnis IOL$218
- MIEBO$139
- XIIDRA$139
- NGENUITY$139
- EYLEA HD$132
- Hydrus Microstent$125
- VERITAS Vision System$109
- Tecnis Simplicity$109
- TEPEZZA$107
- XIPERE$105
How this compares
$6,246 in reported general payments places this provider in the 90th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 35 | $16,001 |
| RestasisCyclosporine | 16 | $9,614 |
| Alphagan PBrimonidine Tartrate | 33 | $8,469 |
| XiidraLifitegrast | 12 | $8,241 |
| LumiganBimatoprost | 18 | $7,285 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $7,093 |
| Prednisolone Acetate | 141 | $5,946 |
| Brimonidine Tartrate | 233 | $5,759 |
| Latanoprost | 519 | $5,070 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 266 | $4,200 |
| Travoprost | 24 | $3,459 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $3,170 |
| Timolol Maleate | 175 | $2,352 |
| Fluorometholone | 19 | $1,886 |
| Dorzolamide Hcl | 115 | $1,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan | $223 | $25,36867 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $21 | $16,00135 claims |
| Bausch & Lomb Americas Inc.Xiidra | $282 | $8,24112 claims |
| AlconSimbrinza | $1,822 | $3,17012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Greenfield
- Judith CoranGreenfield$3K
- Cole RojasGreenfield$3K
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.